Regkirona (regdanvimab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The regkirona (regdanvimab) market research report is one of a series of new reports that provides regkirona (regdanvimab) market statistics, including the regkirona (regdanvimab) industry global market size, regional shares, competitors with the regkirona (regdanvimab) market share, detailed regkirona (regdanvimab) market segments, market trends, and opportunities, and any further data you may need to thrive in the regkirona (regdanvimab) industry. This regkirona (regdanvimab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the rising prevalence of chronic and degenerative diseases, the rising prevalence of autoimmune diseases, the increasing acceptance of biologic drugs, the rising incidence of inflammatory diseases, and the increasing focus on il-6 as a therapeutic target. Major trends in the forecast period include advancements in stem cell and regenerative medicine, adoption of telemedicine and remote monitoring, technological innovations in immunotherapy, 3D bioprinting, and tissue engineering and technological integration in healthcare.

The rising prevalence of autoimmune diseases is expected to drive the growth of the regkirona (regdanvimab) market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, tissues, or organs, causing inflammation and damage. Factors contributing to the growing incidence of autoimmune diseases include genetic predisposition, environmental triggers, poor diet, chronic stress, hormonal changes, increased awareness, better diagnostic capabilities, and an aging population. Regkirona helps by reducing the risk of exacerbations in autoimmune diseases through its prevention of severe COVID-19 infections that can trigger immune system dysregulation. For example, in November 2024, Versorgungsatlas.de reported that, in 2022, 8.61% of the insured individuals in Germany were diagnosed with at least one autoimmune disease. This rise in autoimmune diseases is contributing to the growth of the Regkirona market.

The growing awareness of personalized medicine is also expected to propel the regkirona market. Personalized medicine tailors treatment plans to individual patients based on their genetic, environmental, and lifestyle factors, aiming to enhance treatment efficacy while minimizing side effects. This approach is gaining traction due to advancements in genomics, improvements in diagnostic technologies, increased support from both the public and the healthcare sector, and the rising demand for treatments that are better suited to individual patients. Regkirona fits into this trend by offering a targeted treatment for COVID-19 based on specific patient characteristics, such as severity and risk factors. For instance, in February 2024, the Personalized Medicine Coalition reported that 16 new personalized treatments for rare diseases were approved by the FDA in 2023, a significant rise from the six approvals in 2022. As awareness of personalized medicine grows, so does the market for Regkirona.

The increasing healthcare spending is another factor driving the growth of the regkirona market. Healthcare spending covers the financial resources allocated for medical services, including hospitals, pharmaceuticals, health insurance, and medical equipment. The rise in healthcare spending can be attributed to factors such as an aging population, technological advancements in medicine, the growing prevalence of chronic diseases, expanded healthcare access, and rising drug prices. Regkirona contributes to controlling healthcare spending by providing an effective COVID-19 treatment that helps reduce hospitalizations, shortens recovery times, and alleviates the economic burden of prolonged medical care. According to the Centers for Medicare & Medicaid Services, U.S. healthcare expenditures grew by 4.1% to reach $4.5 trillion in 2022, with state and local government healthcare expenditures increasing by 6.5%. The increasing spending on healthcare is also spurring the growth of the Regkirona market.

The key company operating in the regkirona (regdanvimab) market is Celltrion Inc.

North America was the largest region in the regkirona (regdanvimab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in regkirona (regdanvimab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the regkirona (regdanvimab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Regkirona, also known as regdanvimab, is a monoclonal antibody treatment for COVID-19 designed to prevent the progression of mild to moderate symptoms in high-risk patients. It works by binding to the spike protein of the SARS-CoV-2 virus, blocking its ability to enter human cells and inhibiting replication.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for regkirona (regdanvimab) include mild-to-moderate COVID-19, severe COVID-19, prevention of disease progression, and post-exposure prophylaxis. Mild-to-moderate COVID-19 refers to cases with symptoms such as fever, cough, and fatigue that can typically be managed at home, with moderate cases involving some shortness of breath but not requiring intensive medical care. Regkirona is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a wide range of end users, including pediatric, adult, and geriatric patients.

The regkirona (regdanvimab) market consists of sales of products including injections, dosage vials, pre-filled syringes, emergency use authorization kits, and co-packaged products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.